相似文献
1
Enhancing cellular cancer vaccines.
Immunotherapy. 2009 May;1(3):495-504. doi: 10.2217/IMT.09.4.
2
Dendritic cells in cancer immunotherapy.
Eur J Immunol. 2010 Aug;40(8):2123-30. doi: 10.1002/eji.201040630.
3
Cancer immunotherapy by fusions of dendritic cells and tumor cells.
Immunotherapy. 2009 Jan;1(1):49-62. doi: 10.2217/1750743X.1.1.49.
4
DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
BMC Immunol. 2013 Aug 14;14:39. doi: 10.1186/1471-2172-14-39.
5
Understanding and activating immunity against human cancer.
Curr Opin Immunol. 2010 Apr;22(2):212-4. doi: 10.1016/j.coi.2010.03.001. Epub 2010 Mar 24.
6
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.
7
Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
J Mol Med (Berl). 2003 Sep;81(9):585-96. doi: 10.1007/s00109-003-0472-5. Epub 2003 Aug 21.
8
Immunogene therapy.
Adv Exp Med Biol. 2012;746:151-65. doi: 10.1007/978-1-4614-3146-6_12.
9
Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.
J Immunol. 2015 Jun 15;194(12):5937-47. doi: 10.4049/jimmunol.1500089. Epub 2015 May 13.
10
Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
Expert Opin Biol Ther. 2004 Nov;4(11):1735-47. doi: 10.1517/14712598.4.11.1735.
引用本文的文献
1
Emerging nanotechnologies for cancer immunotherapy.
Exp Biol Med (Maywood). 2016 May;241(10):1116-26. doi: 10.1177/1535370216647123. Epub 2016 May 4.
2
Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.
J Cancer. 2010 Nov 29;1:230-41. doi: 10.7150/jca.1.230.
3
Trends in cancer immunotherapy.
Clin Med Insights Oncol. 2010 Jul 14;4:67-80. doi: 10.4137/cmo.s4795.
本文引用的文献
1
Future of idiotypic vaccination for B-cell lymphoma.
Expert Rev Vaccines. 2009 Jan;8(1):43-50. doi: 10.1586/14760584.8.1.43.
2
CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Expert Opin Biol Ther. 2009 Jan;9(1):71-8. doi: 10.1517/14712590802614538.
3
Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays.
J Immunol Methods. 2009 Feb 28;341(1-2):50-8. doi: 10.1016/j.jim.2008.10.016. Epub 2008 Nov 28.
4
HPV and cervical cancer: updates on an established relationship.
Postgrad Med. 2008 Nov;120(4):7-13. doi: 10.3810/pgm.2008.11.1928.
5
Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
Clin Cancer Res. 2008 Nov 15;14(22):7188-95. doi: 10.1158/1078-0432.CCR-08-0994.
6
Immune therapy for cancer.
Annu Rev Immunol. 2009;27:83-117. doi: 10.1146/annurev.immunol.021908.132544.
7
Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.
Cancer Immun. 2008 Nov 13;8:15.
8
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
J Immunol. 2008 Nov 15;181(10):6955-63. doi: 10.4049/jimmunol.181.10.6955.
9
DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Clin Cancer Res. 2008 Nov 1;14(21):6933-43. doi: 10.1158/1078-0432.CCR-08-1257.
10
Vaccines for lymphomas: idiotype vaccines and beyond.
Blood Rev. 2009 May;23(3):137-42. doi: 10.1016/j.blre.2008.09.001. Epub 2008 Oct 31.
Zotero 插件